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Abstract
Lynch syndrome (LS) is an autosomal dominant inherited disorder due to pathogenic variations in the mismatch repair genes, which predisposes 
to malignancies, most commonly colon and endometrial carcinoma. Muir-Torre syndrome is a subset of LS with cutaneous sebaceous adenoma 
and keratoacanthoma in addition to the malignancies. Renal cell carcinoma (RCC) in patients with LS is extremely rare. Only 26 cases have 
been reported and among them, only two cases of papillary RCC. We report a case of synchronous papillary RCC and colonic adenocarcinoma 
in an 85-year-old male with Lynch/Muir-Torre syndrome. The LS was diagnosed when he presented with multiple sebaceous adenomas and 
genetic testing showed a pathogenic variant in MSH6 mismatch repair gene. A colonoscopy at that time showed multiple tubular adenomas 
with high-grade dysplasia. He was lost to follow-up and presented with gastrointestinal bleeding after 20 years. A right colonic mass, and a solid 
mass in the lower pole of the right kidney, was detected by imaging. Right Colectomy showed a T3N0 mucin-producing adenocarcinoma. Right 
nephrectomy showed a T3a papillary RCC which was microsatellite stable with MSH6, and KRAS mutation. The 36-month follow-up exams 
showed additional sebaceous neoplasms, and an absence of metastatic carcinoma. Analysis of the reported cases of RCC in LS show clear cell 
RCC as the most common type. These tumors showed MLH1 mutation most commonly, unlike the urothelial malignancies in LS which involve 
MSH2. Among the 4 cases of RCC with MSH6 mutation, three were in females, indicating some gender differences.
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Lynch syndrome (LS), an autosomal dominant inherited 
disorder, is the most common cause of hereditary colorectal 
carcinoma. It is associated with germline pathogenic vari-
ants in the DNA mismatch repair (MMR) genes including 
MLH1 (mutL homolog 1), MSH2/MSH6 (mutS homolog 
2 or 6), and PMS2 (PMS1 homologue 2). Rarely, it can 
also be caused by a deletion in the EPCAM (epithelial cell 
adhesion molecule) gene, which leads to epigenetic silenc-
ing of MSH2. Colorectal and endometrial cancers are the 
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predominant malignancies associated with LS (1, 2). Other 
malignancies associated with LS include cancers of the stom-
ach, small intestine, breast, ovary, upper urinary tract, blad-
der, hepatobiliary tract, and brain. The routine screening for 
genetic colorectal adenocarcinoma by immunohistochemis-
try (IHC) and/or Microsatellite instability (MSI) testing has 
led to better detection and an increased understanding of 
LS. LS accounts for about 3% of newly diagnosed colorec-
tal carcinoma (1) and 3% of newly diagnosed endometrial 
carcinoma (2). Most commonly, the germline defect involves 
pathogenic variants in MLH1 or MSH2 genes.
A subset of patients with LS develops visceral malignan-
cies associated with cutaneous sebaceous adenomas and 
keratoacanthoma, which is known as Muir-Torre syndrome 
(MTS). Although LS and MTS share a defect in one of the 
4 MMR genes, a few studies have shown that the frequency 
of the MMR defect in patients with MTS mostly involves 
MSH2 (3). About 5% of the upper urinary tract urothelial 
carcinomas are associated with LS (4). Recent studies have 
shown increased frequency of pathogenic variants in MSH2 
in urological malignancies (5, 6).
Cases of renal cell carcinoma (RCC) in LS have been rarely 
described. An extensive PubMed search revealed 26 cases of 
possible RCC in LS patients (7–11). Here, we encountered 
a case of papillary RCC (PRCC) in a LS/MTS patient with 
germline MSH6 pathogenic variant. These findings serve to 
expand the spectrum of urological malignancies in LS and 
emphasize the need to screen for synchronous and/or meta-
chronous neoplasms in this patient population.
Clinical History
This 85-year-old white male initially presented at the age of 
62 years with multiple cutaneous nodules in the head and 
neck region, diagnosed as multiple sebaceous adenomas. 
This prompted an investigation for visceral malignancies 
and genetic testing. Colonoscopy showed multiple tubular 
adenomas in the descending and sigmoid colon and high-
grade dysplasia in the transverse colon. Genetic testing 
showed a pathogenic variant in MSH6 Exon 9 (c.3980_3983, 
dupATCA (p.L1330Vfs’12)). In addition a heterozygous 
novel variant of uncertain significance (c.8419A>G(p.
T2807A) in the APC gene was also detected. Since he did not 
have the typical presentation of polyposis and lack of cer-
tainty regarding pathogenicity of the APC variant as well as 
presence of pathogenic variant in the MSH6 gene, a diagno-
sis of LS was made. Subsequently, multiple sebaceous ade-
nomas were removed. At the age of 82 years, he presented 
with rectal bleeding and anemia. Abdominal computerized 
tomography scan showed a 6.8 × 6.6 × 8 cm mass in the right 
colon, and a 2.5 × 3.4 × 3.3 cm solid mass on the lower pole 
of the right kidney involving the hilum (Figure 1A), multi-
ple hypodense nonenhancing lesions involving both lobes of 
the liver, and a 2.5 × 2.8 cm hypodense lesion in the body of 
the pancreas. The subsequent subtotal colectomy showed a 
T3N0 mucin-producing adenocarcinoma in the cecum. The 
wedge biopsy of the liver lesion at the same time showed 
a sclerosed hemangioma. The renal mass biopsy showed a 
PRCC. Three months later, a right nephrectomy was per-
formed. Clinical follow-up 3 years after the resection shows 
Figure 1: The Computerized Tomography (A) and the gross photograph (B) of the renal mass showing a well circumscribed tan 
brown mass in the right kidney extending into the renal hilum.
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Table 1: List of neoplasms in this patient.
Year Tumor site Tumor type




Sebaceous adenoma, skin 
squamous carcinoma
Tubular adenoma with high-
grade dysplasia and multiple 
tubular adenoma
2007 Chest Sebaceous adenoma
2010 Nose Sebaceous adenoma and 
squamous carcinoma
2014 Neck Sebaceous adenoma
2015 Cheek Sebaceous adenoma
2016 Scalp Sebaceous adenoma
2017 Cecum and 
right colon
Kidney 
Adenocarcinoma of cecum 
and tubulovillous adenoma 
with high-grade dysplasia of 
right colon
Papillary renal cell carcinoma








2020 Right shoulder Sebaceous adenoma
multiple additional sebaceous adenomas involving the head 
and neck area and sebaceous carcinoma involving the eye-
lid. The pancreatic lesion is stable, and a biopsy was not per-
formed. The timeline of the various tumors in this patient is 
shown in Table 1. There is no evidence of metastatic colon 
or RCC.
Pathologic Evaluation
The multiple sebaceous adenomas histologically showed 
dermal tumors with varying proportions of basaloid cells 
and sebaceous cells with cystic changes (Figure 2A and B). 
The pathologic evaluation of the colonic tumor showed a 
7.5 × 7.2 × 4.3 cm fungating mass within the cecum. His-
tologically, the tumor was a high-grade adenocarcinoma 
with mucin production and invading the subserosal adipose 
tissue. Tumor infiltrating lymphocytes or germinal centers 
were not seen (Figure 2C and D). Strong nuclear expres-
sion of MLH1, PMS2, and MLH2 mismatch repair proteins 
was seen in the adenocarcinoma by IHC. Faint MSH6 was 
expressed in about 3% of the nuclei. The tumor was staged 
as T3N0.
The pathological evaluation of the kidney showed a 
3.4 × 3.3 × 3.0 cm well-circumscribed solid brown mass in 
the lower pole, extending into the hilum and perinephric 
fat (Figure 1B). Histologically, the tumor showed a mass 
without a capsule blending with the uninvolved renal paren-
chyma. Dense sclerotic stroma was present between clus-
ters of tumor cells. The neoplasm showed a 90% papillary 
architecture with thin fibrovascular core, and occasional 
foamy histiocytes. The papillae were lined by a single layer 
of columnar cells with an abundant eosinophilic granular 
cytoplasm. The nucleus was low grade, round, and uniform 
with fine chromatin, placed away from the basal lamina with-
out pseudostratification. The nuclear features were classified 
as ISUP grade 2. Focal areas of hemorrhage and cytoplas-
mic hemosiderin pigment in the tumor cells were present. 
Psammomatous calcification was absent (Figure 3A–F). 
IHC showed focal patchy positivity for AE1/AE3 and dif-
fuse membranous staining for epithelial membrane antigen 
(EMA). There was a strong, diffuse cytoplasmic expression 
of vimentin, AMACR, luminal membranous expression of 
CD10, and nuclear expression of PAX8 (Figure 4A–F). The 
CAIX stain showed focal positivity. Cytokeratin 7 (CK7), 
high molecular weight cytokeratin, GATA3, and CD117 
stains were negative in the tumor cells. These immunohisto-
chemical features were most consistent with PRCC, type 2. 
IHC for mismatch repair proteins showed faint expression 
of MSH6 (1% of nuclei) and strong nuclear expression of 
MLH1, MSH2, and PMS2 (Figure 5A–D). The tumor was 
staged as T3a with sinus and perinephric fat invasion. Vascu-
lar invasion was not seen.
The Foundation Medicine next-generation sequencing 
(NGS) analysis of the renal tumor was performed. The 
genomic abnormalities included ARID1A S90fs*11, MSH6 
L1330fs*12, SETD2 N1725fs*3, and STAG2 E143fs*3. In 
addition, variants of unknown significance (VUS) were 
detected in the tumor. These included APC, EGFR, FANCC, 
FGF14, KDM6A, KRAS, MLL2, and REL. The renal tumor 
was microsatellite stable.
Discussion
There has been an increasing understanding of LS attributed 
to pathogenic variants in one of the four mismatch repair 
(MMR) genes, namely, MLH1, MSH2, MSH6, and PMS2. 
Pathogenic variants in the MMR genes lead to abnormal 
microsatellite sequences referred to as MSI. The National 
Cancer Institute recommends five markers as the screen-
ing tool for MSI. These include three dinucleotide repeats 
(D2S123, D5S346, and D17S250) and two mononucleotide 
repeats (BAT25, BAT26). Identification of three of the 
five markers is considered positive for MSI (3). The MSI 
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Figure 2: (A) Sebaceous adenoma in the dermis with cystic dilatation (Hematoxylin and Eosin ×40). (B) Proliferation of ger-
minative cells in the sebaceous adenoma (Hematoxylin and Eosin ×200). (C) Low magnification view of the colonic adenocar-
cinoma with normal colon on the right and the adenocarcinoma with mostly solid architecture (Hematoxylin and Eosin ×40). 
(D) Poorly differentiated adenocarcinoma of colon with pleomorphic tumor cells and poorly formed glands with some extracel-
lular and intracellular mucin (Hematoxylin and Eosin ×200).
predisposes to the development of multiple malignancies. 
The malignancies associated with LS commonly include col-
orectal carcinoma and endometrial cancer. Other malignant 
sites include breast, ovary, stomach, small bowel, urinary 
tract, hepatobiliary tract, and brain. A subset of LS patients 
also presents with cutaneous sebaceous adenomas and kera-
toacanthoma, called the MTS. Analysis of LS patients with 
cancer has shown that the germline variants involve MLH1 
and MSH2 genes in 60–80% of the cases. Only a minority of 
cases involves MSH6 and PMS2 (12). On the other hand, 
germline variant analysis in patients with MTS showed the 
involvement of MSH2 in 89% of the cases and MLH1 in 
11% of the cases (3). Similarly, germline variant analysis in 
urothelial carcinoma patients with LS has shown frequent 
involvement of MSH2 and MSH6 (5, 6). These studies 
indicate that the clinical spectrum of malignancies depends 
upon which gene is involved in the pathogenesis. The increas-
ing understanding of the clinical manifestations can lead to 
appropriate screening and prevention strategies.
RCC is uncommonly reported in LS. Extensive literature 
search revealed 26 other cases of possible RCC in LS patients 
(7–11). The details of these cases are shown in Table 2. There 
were nine clear cell RCC and three cases of PRCC including 
the current case. Histological subclassification is not avail-
able in 15 cases. Clear cell RCC appears to be the most com-
mon tumor type in LS. The age at presentation ranged from 
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Figure 3: Hematoxylin- and eosin-stained sections of the renal tumor (A). Low magnification showing a well-circumscribed 
tumor with papillary structures and normal kidney on the right (×40) (B). Well-circumscribed papillary tumor with fibrous septa 
separating the tumor (×40) (C). Papillary architecture of the tumor with thin fibrovascular core (×100) (D). The tumor cells have 
abundant granular eosinophilic cytoplasm and a round nucleus placed away from the basal lamina (×400) (E). Papillary tumor 
with foamy histiocytes (×200) and F. Papillary tumor with hemosiderin pigment (×200) (F).
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Figure 4: Immunohistochemical stains showing (A) Focal staining for AE1/AE3. (B) Membranous staining for epithelial mem-
brane antigen (EMA). (C) Diffuse cytoplasmic staining for AMACR. (D) Diffuse nuclear staining for PAX8. (E) Focal staining 
for CAIX. (F) Diffuse strong luminal membranous staining for CD10.
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Figure 5: Immunohistochemical stain for mismatch repair proteins showing loss of expression of MSH6 and preserved nuclear 
expression of MLH1, PMS2, and MSH2.
47 to 82 years among men and 57–67 years among women. 
The incidence of these tumors in female patients is much 
higher than the sporadic tumors with a male to female ratio 
of 1:1 compared to 2:1 in the general population. Unlike the 
upper tract urothelial carcinoma, which are more commonly 
associated with MSH2 variants, RCC was associated with 
MLH1 variants, which was seen in 16 cases (57.1%). Variants 
in MSH2 were seen in 7 cases (25%) and in MSH6 in 4 cases 
(14.8%). Interestingly, three out of four patients with the 
MSH6 variants were females. In the study by Therkildsen et 
al., the incidence of RCC was higher in the Danish patients 
with LS compared to the general population (10). This was 
not seen in the study from Finland (7).
The MSH6 gene is located in the short arm of chromo-
some 2, close to MSH2. Abnormalities in the MSH6 gene 
were first discovered in studies involving hereditary nonpol-
yposis colorectal cancers, from 5 Japanese families who did 
not fulfill the Amsterdam criteria and had no pathogenic 
variants in MLH1 and MSH2 but had a family history of 
endometrial and ovarian cancers. Population-based studies 
indicate higher pathogenic allele frequency rate for MSH6 
and PMS2, but with variable penetrance (13). MSH6 is not 
involved in the repair of dinucleotide repeats and only the 
mononucleotide repeats are involved. When a pathogenic 
variant in the MSH6 gene is suspected, a panel of five mono-
nucleotides (NR21, BAT25, BAT26, NR24, and NR22) 
Papillary renal cell carcinoma in Lynch syndrome
 Journal of Kidney Cancer and VHL 2021; 8(2): 8–19  15
Table 2: Reported cases of renal cell carcinoma in Lynch syndrome.
Case Age/Sex Mutation type Renal cell carcinoma Stage/grade Other tumors Ref
1 77/NP MLH1, ex 16 RCC, subtype NP T1,N0,G2 NP (7)
2 55/NP MLH1, ex 16 RCC, subtype NP T2,N0,G2 NP (7)
3 56/NP MLH1, ex 16 RCC, subtype NP T3,N0,G2 NP (7)
4 88/NP MLH1, ex 16 Not resected NP (7)
5 62/NP MLH1, ex 16 RCC, subtype NP T1,N0,G2 NP (7)
6 62/NP MLH1, ex 16 RCC, subtype NP T3,N1,G2 NP (7)
7 65/NP MLH1, ex 3 RCC, subtype NP T1,N0,G2 NP (7)
8 64/NP MLH1, ex 6 RCC, subtype NP T1,N0,G1 NP (7)
9 60/NP MLH1, ex 16 RCC, subtype NP T1,N0,G3 NP (7)
10 47/NP MLH1, ex 6 RCC, subtype NP T3,N0,G2 NP (7)
11 65/F MSH6 (NP) Clear cell (No MTS) NP NP (8)
12 60/F MSH6(3311delTT) Clear cell T1b,Nx,G2 Colon and endometrium (9)
13 67/F MSH2 c.1750+ST>A Clear cell T1b Colon (10)
14 61/M MSH2 c.368delC Clear cell T2 Colon (10)
15 50/M MSH2 c.368delC Clear cell T2 None (10)
16 61/M MSH2 c.1176C>T Papillary T1a Colon, ureter, and renal pelvis (10)
17 66/F MLH1 c.1852_ 
1854delAAG
Clear cell T3a None (10)
18 47/M MLH1 c.1667+ 
2delTCAinsATTT
Clear cell T1a None (10)
19 61/M MLH1 c.1667+ 
2delTCAinsATTT
Clear cell T2 Gastric (10)
20 62/F MSH6 c.1444C>T Clear cell T3a Ovarian (10)
21 82/M MLH1 c.1732-2A>T NP NP Skin, colon, and small bowel (10)
22 58/M MLH1 
c.1852_1854delAAG
NP NP Colon (10)
23 59/F MLH1 c.1667+ 
2delTCAinsATTT
NP T3a Endometrium (10)
24 82/M MSH2 c.942+3A>T NP NP Colon (10)
25 57/F MSH2 c.892C>T NP NP None (10)
26 61/F MSH2, but no loss of 
expression of MMR 
protein in papillary RCC
Papillary, type 2 T1a Ureter, colon, and 
endocervix
(11)
27 85/M  MSH6 Exon 9 (C3980-
3983, dup ATCA)




NP: Not provided  
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is recommended to assess the MSI status (3). There have 
been relatively few publications of isolated MSH6 variants. 
A  large study of 113 families with MSH6 variant carriers 
from multiple countries has shown some differences in pre-
sentations and in malignancies associated with MSH6. The 
presentation of malignancies is at a much later age extend-
ing to 70 and 80 years as seen in our patient who presented 
with the adenocarcinoma at the age of 82 years. These stud-
ies suggest long-term screening requirement for patients 
with the MSH6 pathogenic variant (13, 14). Endometrial 
carcinoma is the most common presentation among women 
with pathogenic variants in this gene, and the women have a 
sixfold increased incidence of other cancers associated with 
LS including ovary, stomach, kidney, ureter, or brain (14). By 
the age of 70 years, 24% of men and 40% of women will be 
diagnosed with LS-associated malignancy and the incidence 
increases to 47 and 65% by the age of 80 years in men and 
women, respectively. The reported studies also show occur-
rence of other malignancies such as lymphoma, leukemia, 
Langerhan’s cell histiocytosis, and testicular germ cell tumors 
with MSH6 variants (3, 15). These studies suggest a different 
set of malignancies must be considered in the screening of 
patients with MSH6 pathogenic variant.
There were six cases of kidney tumors in the study of 
pure MSH6 variants by Baglietto et al. (14), but the type of 
tumor, whether urothelial carcinoma or RCC, was not spec-
ified. The age of presentation of renal tumors ranged from 
39 to 75 years, indicating earlier presentation than the spo-
radic tumors in some patients. It is also interesting to note 
that four of the six renal tumors in this report were among 
women. Similarly, in our review, there were four RCCs asso-
ciated with MSH6 variants including the current case. There 
were three cases of clear cell RCC, all in females, none of 
whom had MTS (8–10). This current report is the only 
case of PRCC in a male with MTS and a pathogenic vari-
ant in MSH6. This indicates that PRCC in these patients is 
extremely uncommon. It is also possible that other sporadic 
tumors may arise in these patients that are not generally seen 
in LS. However, the loss of expression of the MSH6 protein 
by IHC and the MSH6 variant in this papillary tumor as 
confirmed by the tumor NGS analysis, confirms this to be 
definitively associated with MSH6.
There have been only three reports of PRCC in LS includ-
ing the current case. The two reported cases of PRCC were 
associated with urothelial carcinoma of the ureter and/or 
renal pelvis. In one case with LS due to the MSH2 variant, 
loss of the MSH2 expression and MSI were present in the 
colon, ureter, and cervical adenocarcinoma, but the PRCC 
of the kidney was microsatellite stable and did not show any 
loss of the MMR proteins. Histologically this tumor was 
described as type 2 PRCC that was confined to the kidney, 
but a photograph of the tumor or the background unin-
volved kidney was not available (11). In the second case of 
papillary carcinoma, the histomorphology of the tumor 
was not described or photographed. It is possible that this 
papillary carcinoma was arising in the background of an 
atrophic/inflamed kidney since both these cases had associ-
ated urothelial carcinoma of the ureter/renal pelvis (10, 11). 
The PRCC in the current case was in a normal functioning 
kidney without an urothelial carcinoma. Our case is the 
first report of PRCC associated with pathogenic variants in 
MSH6 in LS/MTS. The MSH6 abnormality (L1330fs*12) 
was also seen in the papillary carcinoma. Other abnor-
malities included ARID1A S90fs*11, SETD2 N1725fs*3, 
and STAG2 E143fs*3. In addition, VUS were detected in 
the tumor in genes such as APC, EGFR, FANCC, FGF14, 
KDM6A, KRAS, MLL2, and REL.
Unlike the RCC with clear cytoplasm, the papillary renal 
tumors have been difficult to classify based on light micro-
scopic and immunohistochemical features. In the 2016 WHO 
classification of renal tumors, the PRCC was subclassified 
into types 1 and 2 as previously reported by Delahunt et al. 
The type 1 PRCC is a well-defined entity showing papillary 
tumor lined by low cuboidal cells with basophilic or amph-
ophilic cytoplasm. The type 2 PRCC shows pseudostratified 
epithelial cells with abundant eosinophilic cytoplasm and 
high-grade nuclei with prominent nucleoli. In the WHO clas-
sification, it was also acknowledged that the type 2 PRCC is 
a heterogeneous group of tumors. The type 2 PRCC must 
be differentiated from other RCCs with papillary architec-
ture. These include hereditary leiomyomatosis and RCC 
(HLRCC), collecting duct carcinoma, renal medullary car-
cinoma, and MiT family translocation carcinoma. HLRCC 
typically shows a PRCC with prominent nucleolus and a 
perinucleolar halo. These tumors show loss of Fumarate 
hydratase and overexpression of 2SC by IHC. The collect-
ing duct carcinoma shows an infiltrating tumor in a desmo-
plastic stroma. The expression of OCT3/4, SMARCB1, and 
p63 differentiates it from type 2 PRCC. The renal medullary 
carcinoma is associated with a clinical history of sickle cell 
trait and shows loss of SMARCB1 by IHC. The MiT family 
translocation carcinomas include tumors with gene fusions 
involving the TFE3 or TFEB locus. The diagnosis is made by 
TFE3 or TFEB break apart fluorescent in situ hybridization 
(FISH) assay, which is more sensitive than the immunohisto-
chemical stains for TFE3 and TFEB.
The oncocytic PRCC was described by many authors 
(16–19), and it was not included in the WHO classification, 
needing further characterization. It has been acknowledged 
by many authors (20, 21) that often PRCC shows features of 
both types 1 and 2 with significant interobserver variability 
making the subclassification more difficult. The comprehen-
sive study by Saleeb et al. (21) subtyped the PRCC into four 
types PRCC1–PRCC4 based on histologic, immunohisto-
chemical, and molecular findings. The PRCC1 and PRCC2 
corresponded with the WHO type 1 and 2, respectively. The 
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PRCC3 had features of both types 1 and 2, while PRCC4 had 
features of oncocytic PRCC. This same study also demon-
strated that the PRCC4 or oncocytic PRCC is positive for 
GATA3 by IHC. Al-Obeidy et al. (22), while reviewing the 
oncocytic PRCC, discovered a distinct subtype of papillary 
renal tumors with papillary or tubular architecture lined by a 
single layer of cuboidal cells with eosinophilic granular cyto-
plasm, with apically located round nucleus away from the 
basal lamina without pseudostratification, which was called a 
papillary renal neoplasm with reverse polarity. These tumors 
showed a male to female ratio of 1:1, ISUP grade 1–2 tumors 
without metastasis after a follow-up of 20 months. Unlike 
types 1 and 2 PRCC, these tumors were positive for GATA3 
and negative for vimentin. The next-generation sequencing 
of 10 of these tumors performed by the same group showed 
KRAS missense variants in eight tumors. This variation 
was absent in 30 types 1 and 2 PRCC that were studied (23). 
One case of GATA3-positive papillary renal neoplasm with 
reverse polarity with KRAS and PIK3CA mutation is also 
described by Lee et al. (24). Similarly, KRAS mutations 
were also observed by Kim and Tong et al. (25, 26) who have 
described KRAS mutations in papillary renal neoplasm with 
reverse polarity, but GATA3 immunohistochemical stain was 
not performed in these two studies. In the study by Bayrak 
et al. (27) KRAS mutation was not detected in the CCRCC, 
Chromophobe RCC, and PRCC. The subtype of PRCC 
examined was not described. These studies indicate that the 
KRAS mutation is seen in oncocytic papillary neoplasms.
The PRCC in this study did not particularly fit into a 
specific type of PRCC. It showed some light microscopic 
features of papillary renal neoplasm with reverse polarity, 
including a papillary architecture with oncocytic cells show-
ing apically placed low-grade nuclei without pseudostratifi-
cation. Interestingly, a KRAS variant was detected in this 
tumor as in papillary tumors with reverse polarity. Fol-
low-up evaluations 36 months after the nephrectomy show 
the absence of metastatic disease. This tumor differed from 
papillary renal neoplasm with reverse polarity by the pres-
ence of rare collections of histiocytes in the papillary fibro-
vascular cores. Immunohistochemically, strong expression of 
vimentin and absence of GATA3 and only focal staining for 
cytokeratin AE1/AE3 was also not compatible with papillary 
renal tumor with reverse polarity. The immunohistochemical 
features were that of type 2 PRCC. The presence of KRAS 
mutation in this tumor suggests that this mutation may not 
be restricted to the papillary renal neoplasm with reverse 
polarity and this entity should be better defined with the 
study of large number of cases.
It is well-known that LS patients may have multiple syn-
chronous or metachronous malignancies (28). In our case, 
mucin-producing colonic adenocarcinoma was synchronous 
with PRCC. Interestingly, it has been reported that patients 
with both colorectal and RCC diagnoses have an increased 
risk for additional malignancies, regardless of whether 
the patient has a hereditary cancer syndrome or not (29). 
Because of the rarity of this entity, the pathologic behavior 
is yet to be determined. But, it emphasizes the importance of 
careful follow-up in such a patient population.
Few unusual and uncommon tumors have also been 
reported in LS, including adrenocortical carcinoma, peri-
toneal mesothelioma (30, 31), pancreatic acinar carcinoma, 
pancreatic neuroendocrine carcinoma (30), low-grade serous 
carcinoma, leiomyosarcoma, liposarcoma, malignant fibrous 
histiocytoma, anaplastic thyroid carcinoma, melanoma, 
breast carcinoma, and prostatic adenocarcinoma (31, 32). 
Whether all these tumors like the renal tumors in this study 
are truly related to LS or are coincidental tumors in a back-
ground of MSI needs to be determined. The study of the 
molecular profiles of different LS-associated tumors by Gyl-
ling et al. (33) showed that LS-associated tumors developed 
by various routes. The level of MSI was variable in the dif-
ferent LS-associated tumors, with high MSI in ureter, stom-
ach, and colonic carcinomas and much lower in renal and 
brain tumors. Similarly, the papillary tumor in this case was 
microsatellite stable. Further studies are necessary for a bet-
ter understanding of the development of these uncommon 
tumors.
Conclusion
We describe the first case of PRCC in a patient with Lynch/
MTS with the MSH6 pathogenic variant. The PRCC showed 
oncocytic cytoplasm with reverse nuclear polarity, and loss 
of MSH6 by IHC and NGS. There was also KRAS muta-
tion, but the tumor was microsatellite stable. This tumor had 
some features of the recently described papillary renal neo-
plasm with reverse polarity, including the KRAS mutation, 
but it was immunohistochemically like type 2 PRCC, suggest-
ing that the KRAS mutation is not unique to papillary renal 
neoplasm with reverse polarity. Including the current case, 27 
cases of RCC have been reported in association with LS.
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